363 related articles for article (PubMed ID: 26808063)
21. [Application of metabolomics in treating polycystic ovary syndrome with berberine based on ultra high performance liquid chromatography-mass spectrometry].
Li Y; Zhang C; Zhang H; Zhao X; Hou L; Xu G
Se Pu; 2014 May; 32(5):464-71. PubMed ID: 25185305
[TBL] [Abstract][Full Text] [Related]
22. The correlation of plasma omentin-1 with insulin resistance in non-obese polycystic ovary syndrome.
Yang HY; Ma Y; Lu XH; Liang XH; Suo YJ; Huang ZX; Lu DC; Qin YF; Luo ZJ
Ann Endocrinol (Paris); 2015 Oct; 76(5):620-7. PubMed ID: 26514948
[TBL] [Abstract][Full Text] [Related]
23. Metabolomics in polycystic ovary syndrome.
Murri M; Insenser M; Escobar-Morreale HF
Clin Chim Acta; 2014 Feb; 429():181-8. PubMed ID: 24368231
[TBL] [Abstract][Full Text] [Related]
24. Quantitative analysis of amino acids and acylcarnitines combined with untargeted metabolomics using ultra-high performance liquid chromatography and quadrupole time-of-flight mass spectrometry.
Roy C; Tremblay PY; Bienvenu JF; Ayotte P
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Aug; 1027():40-9. PubMed ID: 27240302
[TBL] [Abstract][Full Text] [Related]
25. Insulin resistance and endocrine characteristics of the different phenotypes of polycystic ovary syndrome: a prospective study.
Panidis D; Tziomalos K; Misichronis G; Papadakis E; Betsas G; Katsikis I; Macut D
Hum Reprod; 2012 Feb; 27(2):541-9. PubMed ID: 22144419
[TBL] [Abstract][Full Text] [Related]
26. Comparison of markers of insulin resistance and circulating androgens between women with polycystic ovary syndrome and women with metabolic syndrome.
Tziomalos K; Katsikis I; Papadakis E; Kandaraki EA; Macut D; Panidis D
Hum Reprod; 2013 Mar; 28(3):785-93. PubMed ID: 23315058
[TBL] [Abstract][Full Text] [Related]
27. Metabonomics reveals plasma metabolic changes and inflammatory marker in polycystic ovary syndrome patients.
Sun L; Hu W; Liu Q; Hao Q; Sun B; Zhang Q; Mao S; Qiao J; Yan X
J Proteome Res; 2012 May; 11(5):2937-46. PubMed ID: 22428626
[TBL] [Abstract][Full Text] [Related]
28. Metabolic aspects of different phenotypes of polycystic ovary syndrome: Iranian PCOS Prevalence Study.
Hosseinpanah F; Barzin M; Keihani S; Ramezani Tehrani F; Azizi F
Clin Endocrinol (Oxf); 2014 Jul; 81(1):93-9. PubMed ID: 24428207
[TBL] [Abstract][Full Text] [Related]
29. Adipocyte fatty acid-binding protein is associated with markers of obesity, but is an unlikely link between obesity, insulin resistance, and hyperandrogenism in polycystic ovary syndrome women.
Möhlig M; Weickert MO; Ghadamgadai E; Machlitt A; Pfüller B; Arafat AM; Pfeiffer AF; Schöfl C
Eur J Endocrinol; 2007 Aug; 157(2):195-200. PubMed ID: 17656598
[TBL] [Abstract][Full Text] [Related]
30. Metabolic alterations associated with polycystic ovary syndrome: A UPLC Q-Exactive based metabolomic study.
Chen X; Lu T; Wang X; Sun X; Zhang J; Zhou K; Ji X; Sun R; Wang X; Chen M; Ling X
Clin Chim Acta; 2020 Mar; 502():280-286. PubMed ID: 31758934
[TBL] [Abstract][Full Text] [Related]
31. Anti-Mullerian hormone and insulin resistance in polycystic ovary syndrome.
Fonseca HP; Brondi RS; Piovesan FX; Miklos TG; Aldrighi JM
Gynecol Endocrinol; 2014 Sep; 30(9):667-70. PubMed ID: 24898132
[TBL] [Abstract][Full Text] [Related]
32. Metabolomics and correlation network analysis of follicular fluid reveals associations between l-tryptophan, l-tyrosine and polycystic ovary syndrome.
Hou E; Zhao Y; Hang J; Qiao J
Biomed Chromatogr; 2021 Mar; 35(3):e4993. PubMed ID: 32986877
[TBL] [Abstract][Full Text] [Related]
33. Endocannabinoid system activation may be associated with insulin resistance in women with polycystic ovary syndrome.
Juan CC; Chen KH; Wang PH; Hwang JL; Seow KM
Fertil Steril; 2015 Jul; 104(1):200-6. PubMed ID: 25935491
[TBL] [Abstract][Full Text] [Related]
34. Adverse metabolic phenotype of adolescent girls with non-alcoholic fatty liver disease plus polycystic ovary syndrome compared with other girls and boys.
Ayonrinde OT; Adams LA; Doherty DA; Mori TA; Beilin LJ; Oddy WH; Hickey M; Sloboda DM; Olynyk JK; Hart R
J Gastroenterol Hepatol; 2016 May; 31(5):980-7. PubMed ID: 26589977
[TBL] [Abstract][Full Text] [Related]
35. [Leptin in patients with polycystic ovary syndrome. Direct correlation with insulin resistance].
Calvar CE; Intebi AD; Bengolea SV; Hermes R; Spinedi E
Medicina (B Aires); 2003; 63(6):704-10. PubMed ID: 14719312
[TBL] [Abstract][Full Text] [Related]
36. Metabolomic Profiling of Pregnancies With Polycystic Ovary Syndrome Identifies a Unique Metabolic Signature and Potential Predictive Biomarkers of Low Birth Weight.
Diboun I; Ramanjaneya M; Ahmed L; Bashir M; Butler AE; Albagha O; Abou-Samra AB; Atkin SL; Mazloum NA; Elrayess MA
Front Endocrinol (Lausanne); 2021; 12():638727. PubMed ID: 34211435
[TBL] [Abstract][Full Text] [Related]
37. UPLC/Q‑TOF‑MS based plasma metabolomics and clinical characteristics of polycystic ovarian syndrome.
Fan X; Jiang J; Huang Z; Gong J; Wang Y; Xue W; Deng Y; Wang Y; Zheng T; Sun A; Luo G
Mol Med Rep; 2019 Jan; 19(1):280-292. PubMed ID: 30431132
[TBL] [Abstract][Full Text] [Related]
38. [Activity and distribution of plasma platelet-activating factor acetylhydrolase in polycystic ovary syndrome patients with insulin resistance].
Wan DH; Fan P; Bai H; Song Q; Liu HW
Zhonghua Fu Chan Ke Za Zhi; 2010 Jan; 45(1):30-4. PubMed ID: 20367923
[TBL] [Abstract][Full Text] [Related]
39. Increased frequency of the DI genotype of the angiotensin-I converting enzyme and association of the II genotype with insulin resistance in polycystic ovary syndrome.
Koika V; Georgopoulos NA; Piouka A; Roupas ND; Karela A; Armeni AK; Katsantoni E; Panidis D
Eur J Endocrinol; 2012 Apr; 166(4):695-702. PubMed ID: 22223701
[TBL] [Abstract][Full Text] [Related]
40. Insulin resistance variability in women with anovulatory and ovulatory polycystic ovary syndrome, and normal controls.
Cho LW; Kilpatrick ES; Keevil BG; Jayagopal V; Coady AM; Rigby AS; Atkin SL
Horm Metab Res; 2011 Feb; 43(2):141-5. PubMed ID: 21234853
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
